Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia

NCT07007312 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT07007312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07007312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
Lead sponsor
Kura Oncology, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
September 26, 2025
Completion date
November 30, 2031
Enrollment
1,300 (estimated)
Sites
136

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)